Skip to content
Disclosery

RHO CAPITAL PARTNERS INC

Follow

13F filer, CIK 1020455, NEW YORK, NY

RHO CAPITAL PARTNERS INC reported $58,841,000 across 4 holdings for the quarter ended 2022-06-30, in a 13F-HR filed 2022-08-01.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-22-001346

Period
2022-06-30
Reported value
$58.8M
Holdings
4
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NGM BIOPHARMACEUTICALS INCexited-3,766,666-$57.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2022

Share positions as resolved from 13F-HR 0001420506-22-001346, largest first. % of portfolio is the value over $58,841,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CHARGEPOINT HLDGS INCCHARGEPOINT HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 4,053,257 shares; 2022Q1: 4,053,257 shares; 2022Q2: 4,053,257 shares 4,053,257$55.5M94.3%0
LIVEONE INCLIVEONE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 3,724,137 shares; 2022Q1: 3,724,137 shares; 2022Q2: 3,724,137 shares 3,724,137$3.19M5.42%0
SENSEONICS HLDGS INCSENSEONICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 159,601 shares; 2022Q1: 159,601 shares; 2022Q2: 159,601 shares 159,601$164K0.28%0
Mersana Therapeutics IncMersana Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 796,458 shares; 2022Q1: 796,458 shares; 2022Q2: 0 shares 0$00%-796,458Value filed as zero, left out of ratios.Amount filed as zero, left out of ratios.

Sold out in Q2 2022

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC3,766,666$57.4Mshares

How Q2 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-22-001346 base2022-08-01acceptance time not in the bulk data set